ANIXA BIOSCIENCES (ANIX) Competitors $3.22 -0.15 (-4.45%) Closing price 04:00 PM EasternExtended Trading$3.30 +0.08 (+2.48%) As of 05:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANIX vs. CMPX, AQST, ITOS, ETON, VIGL, HUMA, CYRX, ATXS, CKPT, and ARCTShould you be buying ANIXA BIOSCIENCES stock or one of its competitors? The main competitors of ANIXA BIOSCIENCES include Compass Therapeutics (CMPX), Aquestive Therapeutics (AQST), iTeos Therapeutics (ITOS), Eton Pharmaceuticals (ETON), Vigil Neuroscience (VIGL), Humacyte (HUMA), CryoPort (CYRX), Astria Therapeutics (ATXS), Checkpoint Therapeutics (CKPT), and Arcturus Therapeutics (ARCT). These companies are all part of the "pharmaceutical products" industry. ANIXA BIOSCIENCES vs. Its Competitors Compass Therapeutics Aquestive Therapeutics iTeos Therapeutics Eton Pharmaceuticals Vigil Neuroscience Humacyte CryoPort Astria Therapeutics Checkpoint Therapeutics Arcturus Therapeutics Compass Therapeutics (NASDAQ:CMPX) and ANIXA BIOSCIENCES (NASDAQ:ANIX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership. Is CMPX or ANIX more profitable? Compass Therapeutics' return on equity of -42.47% beat ANIXA BIOSCIENCES's return on equity.Company Net Margins Return on Equity Return on Assets Compass TherapeuticsN/A -42.47% -38.31% ANIXA BIOSCIENCES N/A -68.17%-60.38% Which has more risk & volatility, CMPX or ANIX? Compass Therapeutics has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500. Comparatively, ANIXA BIOSCIENCES has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500. Do institutionals & insiders have more ownership in CMPX or ANIX? 68.4% of Compass Therapeutics shares are held by institutional investors. Comparatively, 29.1% of ANIXA BIOSCIENCES shares are held by institutional investors. 29.8% of Compass Therapeutics shares are held by insiders. Comparatively, 25.3% of ANIXA BIOSCIENCES shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media prefer CMPX or ANIX? In the previous week, ANIXA BIOSCIENCES had 4 more articles in the media than Compass Therapeutics. MarketBeat recorded 5 mentions for ANIXA BIOSCIENCES and 1 mentions for Compass Therapeutics. Compass Therapeutics' average media sentiment score of 1.89 beat ANIXA BIOSCIENCES's score of 1.32 indicating that Compass Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Compass Therapeutics Very Positive ANIXA BIOSCIENCES Positive Which has stronger earnings & valuation, CMPX or ANIX? ANIXA BIOSCIENCES has lower revenue, but higher earnings than Compass Therapeutics. ANIXA BIOSCIENCES is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCompass Therapeutics$850K517.33-$49.38M-$0.41-7.76ANIXA BIOSCIENCES$210K493.89-$12.55M-$0.38-8.47 Do analysts recommend CMPX or ANIX? Compass Therapeutics presently has a consensus price target of $12.67, indicating a potential upside of 298.32%. ANIXA BIOSCIENCES has a consensus price target of $9.00, indicating a potential upside of 179.50%. Given Compass Therapeutics' higher possible upside, research analysts clearly believe Compass Therapeutics is more favorable than ANIXA BIOSCIENCES.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Compass Therapeutics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10ANIXA BIOSCIENCES 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 SummaryCompass Therapeutics beats ANIXA BIOSCIENCES on 10 of the 14 factors compared between the two stocks. Get ANIXA BIOSCIENCES News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANIX vs. The Competition Export to ExcelMetricANIXA BIOSCIENCESMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$108.55M$3.03B$5.74B$9.51BDividend YieldN/A2.40%4.60%3.99%P/E RatioN/A21.1828.1120.03Price / Sales493.89339.44461.57200.15Price / CashN/A43.2336.5559.01Price / Book5.468.368.655.90Net Income-$12.55M-$55.19M$3.25B$258.66M7 Day Performance-6.40%5.89%4.20%2.23%1 Month Performance-2.72%17.63%10.82%12.76%1 Year Performance11.42%5.09%34.70%19.36% ANIXA BIOSCIENCES Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANIXANIXA BIOSCIENCES3.1012 of 5 stars$3.22-4.5%$9.00+179.5%+21.7%$108.55M$210K0.005Positive NewsCMPXCompass Therapeutics3.025 of 5 stars$2.92+8.1%$12.67+333.8%+230.9%$403.79M$850K-7.1220Positive NewsAQSTAquestive Therapeutics1.7086 of 5 stars$4.03+0.5%$10.14+151.7%+24.6%$400.30M$57.56M-6.83160ITOSiTeos Therapeutics3.18 of 5 stars$10.35+0.6%$15.86+53.2%-38.1%$396.09M$35M-3.4090News CoverageAnalyst RevisionETONEton Pharmaceuticals2.1782 of 5 stars$14.54+0.3%$29.67+104.0%+333.0%$389.96M$39.01M-80.7820Positive NewsVIGLVigil Neuroscience3.9363 of 5 stars$8.07+0.2%$10.80+33.8%+89.4%$384.83MN/A-3.9440Positive NewsHUMAHumacyte1.6564 of 5 stars$2.47+6.9%$11.71+374.3%-66.9%$383.14M$517K-3.58150News CoverageAnalyst ForecastCYRXCryoPort1.7838 of 5 stars$7.50-0.7%$10.88+45.0%-7.0%$376.05M$228.38M-3.211,186ATXSAstria Therapeutics1.9456 of 5 stars$6.62+3.9%$30.00+353.2%-42.8%$373.57MN/A-3.5430Positive NewsCKPTCheckpoint Therapeutics0.3066 of 5 stars$4.26flat$4.33+1.7%N/A$370.71M$41K-2.3210ARCTArcturus Therapeutics2.1639 of 5 stars$13.31-3.4%$54.00+305.7%-33.2%$360.98M$131.27M-5.26180 Related Companies and Tools Related Companies Compass Therapeutics Alternatives Aquestive Therapeutics Alternatives iTeos Therapeutics Alternatives Eton Pharmaceuticals Alternatives Vigil Neuroscience Alternatives Humacyte Alternatives CryoPort Alternatives Astria Therapeutics Alternatives Checkpoint Therapeutics Alternatives Arcturus Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANIX) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredThe big winner of Crypto week?It’s Crypto Week at the White House — and the sector is moving from fringe to full-scale adoption. With Bit...Weiss Ratings | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ANIXA BIOSCIENCES INC Please log in to your account or sign up in order to add this asset to your watchlist. Share ANIXA BIOSCIENCES With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANIX Stock Alerts